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Background. A pilot programme to treat multidrug-resistant TB (MDR-TB) was implemented in Karakalpakstan, Uzbekistan in
2003. This region has particularly high levels of MDR-TB, with 13% and 40% among new and previously treated cases,
respectively. Methodology. This study describes the treatment process and outcomes for the first cohort of patients enrolled
in the programme, between October 2003 and January 2005. Confirmed MDR-TB cases were treated with an individualised,
second-line drug regimen based on drug susceptibility test results, while suspected MDR-TB cases were treated with
a standardised regimen pending susceptibility results. Principal Findings. Of 108 MDR-TB patients, 87 were started on
treatment during the study period. Of these, 33 (38%) were infected with strains resistant to at least one second-line drug at
baseline, but none had initial ofloxacin resistance. Treatment was successful for 54 (62%) patients, with 13 (15%) dying during
treatment, 12 (14%) defaulting and 8 (8%) failing treatment. Poor clinical condition and baseline second-line resistance
contributed to treatment failure or death. Treatment regimens were changed in 71 (82%) patients due to severe adverse
events or drug resistance. Adverse events were most commonly attributed to cycloserine, ethionamide and p-aminosalicylic
acid. Extensively drug resistant TB (XDR-TB) was found among 4 of the 6 patients who failed treatment and were still alive in
November 2006. Conclusions. While acceptable treatment success was achieved, the complexity of treatment and the
development of XDR-TB among treatment failures are important issues to be addressed when considering scaling up MDR-TB
treatment.
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INTRODUCTION
Since 1997, when the first global surveillance of tuberculosis (TB)
drug resistance was reported, data on the threat that drug-resistant
TB poses to TB control internationally have been growing [1,2,3].
Multidrug-resistant TB (MDR-TB), defined as resistance to the
two most important anti-TB drugs isoniazid and rifampicin, has
been found in all regions surveyed and is at critical levels in some
areas, particularly among countries of the former Soviet Union.
MDR-TB is significantly more difficult to treat than drug-
susceptible TB, requiring the use of less effective second-line drugs,
which are often associated with major side effects. In response to
the high cost of second-line drugs and the lack of treatment options
for patients infected with MDR-TB, the World Health Organi-
zation (WHO), along with other partners, launched the Green
Light Committee (GLC) in 2000 [4]. The aim of the GLC is to
facilitate the treatment of patients with MDR-TB through
extending existing directly observed treatment, short-course
(DOTS) programmes for TB treatment, termed DOTS-Plus.
Support includes the provision of technical support and preferen-
tially priced drugs.
By the end of 2006, the GLC had endorsed 53 MDR-TB
control projects, encompassing the treatment of more than 25,000
patients [5]. Results from 5 of these projects have been published,
with treatment success ranging from 59% in the Philippines to
83% in the Russian Federation [5]. These results are in general
a considerable improvement over those reported prior to the
development of the DOTS-Plus programmatic approach [6].
However, despite the large numbers approved for MDR-TB
treatment, the feasibility of scaling up MDR-TB treatment to
cover all patients in need has not been demonstrated in resource-
limited settings. This is significant in light of recent calls to scale up
MDR-TB treatment to avoid the development of what is now
classified as extensively drug-resistant TB (XDR-TB). XDR-TB,
defined as MDR-TB with additional resistance to a fluoroquino-
lone and a second-line injectable agent, is often considered
untreatable and was responsible for a well-publicised outbreak in
South Africa [7].
Karakalpakstan is a semiautonomous region in the west of
Uzbekistan, characterized by poverty, severe environmental
degradation and slow reform of health services [8,9]. In response
to an identified need, the medical aid agency Me ´decins Sans
Frontie `res (MSF), in cooperation with the Ministry of Health,
began the progressive implementation of a DOTS program for TB
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complete, covering a population of around 1.2 million, with a case
notification rate of 482/100,000/year for all forms of TB [10].
However, poor treatment outcomes prompted a survey of TB drug
resistance in 2001–2002, which found extremely high rates of
MDR-TB; 13% among new cases and 40% among TB patients
who had received prior TB treatment [10]. To date, these figures
are the only data on the prevalence of MDR-TB in Uzbekistan.
These high levels, in turn, prompted the initiation of a pilot
DOTS-Plus project to provide treatment for patients infected with
drug-resistant TB strains in two of the 17 districts in Karakalpak-
stan. The program was started in the civilian sector in the main
city of Nukus (population 260,600) and a rural district, Chimbay
(population 97,700), some 50–100 km from Nukus. The aim was
to assess the feasibility of DOTS-Plus in both the relatively
accessible city and a rural area with low population density, poor
transport and large distances. These districts had functioning
DOTS programs for at least 2–3 years prior to the implementa-
tion of DOTS-Plus. The DOTS program utilised standard first-
line treatment regimens, along with direct sputum smear
microscopy for diagnosis, as recommended by WHO [11].
Despite the adoption of DOTS, both first- and second-line anti-
TB drugs are available for private sale in Karakalpakstan.
The pilot DOTS-Plus project received GLC approval to treat
100 patients in early 2003, with the first patient starting treatment
in October 2003. In late 2004, a further GLC application was
submitted and approval was given to enrol up to 800 patients on
treatment. As of June 2007, 433 patients have been registered in
the program. Here we report treatment outcomes for the first
cohort of patients treated in the DOTS-Plus pilot project in
Karakalpakstan, Uzbekistan and the risk of XDR-TB among
treatment failures.
MATERIALS AND METHODS
Setting and study design
Since this pilot program had initial approval to treat only 100
patients, the program was implemented separately from the
DOTS program. This was based on the realisation that not all
patients with MDR-TB would be able to be treated. For inpatient
care of patients with MDR-TB, an unused hospital on the outskirts
of Nukus City was reorganized in 2003 to house 50 patients and
has since been upgraded to 75 beds. A separate outpatient clinic
was established in Nukus City, and existing DOTS clinics were
utilized to provide ambulatory services for DOTS-Plus in
Chimbay district. In addition, a laboratory capable of culture
and drug susceptibility testing (DST) was established in Nukus.
The pilot program is a collaborative effort between MSF, the
Ministries of Health in Karakalpakstan and Uzbekistan and the
National Reference Centre for Mycobacteria in Germany.
The first cohort of patients to be enrolled in the DOTS-Plus
pilot project consisted of: patients found to be infected with MDR-
TB during the initial drug resistance survey [10] and alive at the
time of first enrolment (confirmed MDR-TB), or recorded as
having previously failed a standard category-2 re-treatment DOTS
regimen (suspected MDR-TB) (Figure 1). Suspected MDR-TB
patients were either started on an empiric treatment regimen
(ETR) or were placed on a waiting list until DST results became
available. This decision was made based on clinical condition and
hospital capacity. All patients were actively sought and further
Figure 1. Patient recruitment and outcomes from MDR-TB treatment October 2003 to January 2005.
doi:10.1371/journal.pone.0001126.g001
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enrolment.
Patients were eligible for treatment if they were: residents of the
two districts, Nukus City and Chimbay; had culture positive
pulmonary TB; had previously been treated in the DOTS
program; and did not have any of the conditions listed in the
exclusion criteria and following assessment by a treatment commit-
tee established for the DOTS-Plus program. Exclusion criteria were
listed as any concomitant medical conditions that in principle
precluded anti-TB treatment. These are described as cirrhosis,
uncontrolled seizure disorder, significant psychiatric disease and
known allergies to second-line anti-TB drugs. Generally, poor
clinical condition was not an exclusion criterion. Patients were also
not excluded based on prior default from TB treatment. For the first
2 years of the program, only adult patients (aged over 16 years)
were eligible for treatment. Since then, children are now eligible for
home-based treatment. Although only patients from the two
districts, Nukus and Chimbay, were eligible for enrolment, a further
two patients with MDR-TB from the drug-resistance survey who
resided in a separate rural district were found to still be alive at the
time of enrolment and were also included.
A small number of suspected MDR-TB patients were found to
be infected with polyresistant strains and were treated accordingly
(Figure 1); they have not been included in this analysis, which
includes only MDR-TB patients enrolled between October 2003
and January 2005. All patients received a detailed explanation of
the treatment protocol and signed a written consent form prior to
treatment. As this was a programmatic evaluation and all data
were collected routinely, ethical approval was not sought prior to
the implementation of the program nor this evaluation.
Treatment regimens and protocol
Suspected MDR-TB patients were started on an ETR consisting
of pyrazinamide, ofloxacin, ethionamide, p-aminosalicylic acid
(PAS), cycloserine and either capreomycin or kanamycin,
depending upon reported previous use of kanamycin. Confirmed
MDR-TB patients were started on an individualised treatment
regimen (ITR) based on the most recent DST profile for that
patient. Both empiric and individualised treatment regimens were
adjusted when more recent DST results became available. In
general, regimens contained at least five drugs to which the
infecting strain was susceptible, including a second-line injectable
agent (either capreomycin or kanamycin) for at least 6 months
after documented sputum culture conversion. The total treatment
duration included a minimum of 18 months of treatment after
culture conversion. Culture conversion was defined as at least 2
negative cultures at least 30 days apart. The duration of
hospitalisation was variable, depending on the use of an injectable
drug in the regimen, clinical condition and availability of family
support. In general, patients were hospitalised for the first
6 months of their treatment. Patients were not tested for HIV at
any stage during treatment.
Sputum smear and culture were conducted monthly, and, when
culture positive, DST was reassessed at 4 months of treatment, or
if a patient was culture positive after previously being culture
negative. Chest radiographs were performed at enrolment, after
3 months of treatment and every 6 months thereafter. Adverse
events were managed rapidly and aggressively, with permanent
removal of a drug from the treatment regimen as a last resort. All
treatment doses of drugs were directly observed, with the
exception of amoxicillin/clavulanate for discharged patients,
where doses were divided across the day, with only the first half-
dose observed. Resectional surgery was not undertaken for any of
the patients in this first cohort. Patients received counselling to
maximise adherence and financial support for transport to
outpatient facilities when discharged from hospital. During
hospitalisation, at least four meals were provided daily, and the
families of patients received a food parcel on a monthly basis while
the patient was still receiving treatment.
Definitions
Treatment outcomes were defined according to recommendations
from the WHO MDR-TB working group [12]. Cure was defined
as at least five negative sputum cultures in the last 12 months of
treatment. A single positive culture was allowed if it was followed
by a minimum of three negative cultures. Patients were classified
as having completed treatment if there were insufficient bacteri-
ological results to classify the patient as cured, but no evidence of
treatment failure. Treatment failure was defined as two or more
positive cultures in the last 12 months of treatment, or if a medical
decision was made to terminate treatment due to poor response or
adverse events. Default was defined as an interruption of two or
more consecutive months to treatment. Patients were recorded as
dead if they died during treatment, regardless of the cause.
Severe clinical condition at treatment initiation was defined as
one or more of the following: ability to walk unaided, resting
respiratory rate $30/min or body mass index (BMI) ,16 kg/m
2.
XDR-TB was defined as MDR-TB with the addition of resistance
to a fluoroquinolone and to either an aminoglycoside or
capreomycin or both [13]. Serious adverse events were defined
as those that resulted in any change to the anti-TB drug regimen,
either changing the dose of a drug, or temporarily or permanently
removing a drug from the regimen.
Laboratory testing
Sputum smear microscopy, culture and DST were conducted
according to international standards in the Nukus mycobacteriol-
ogy laboratory. Smears were assessed using fluorescence micros-
copy and culture using Lowenstein-Jensen media. All cultures were
also sent from Nukus to the supranational reference laboratory in
Borstel, Germany for repeat DST. For this cohort, all DST results
reported were from the Borstel laboratory. DST was conducted for
5 first-line drugs (isoniazid, rifampicin, ethambutol, streptomycin,
pyrazinamide) and 6 second-line drugs (capreomycin, amikacin,
ofloxacin, ethionamide, cycloserine, PAS), as described previously
[14].
Data collection and analysis
A paper-based and computerized medical record system was
instituted from the start of the pilot program. A system of data
collection forms for enrolment and treatment follow-up were
developed and the data entered routinely into an Epi-info-based
database created specifically for the program (Epi-info version
6.04, CDC, Atlanta, GA). This system was designed to record
significantly more information than that routinely collected in the
DOTS program, where patient data from the entire treatment
course were recorded on a single, two-sided treatment card.
During this analysis, a few data points not routinely recorded on
the database were found to be important and were retrospectively
compiled from the paper-based medical record. These included
resting respiratory rate and ability to walk unaided at admission.
These changes will be incorporated into a new database system for
MDR-TB treatment currently under development.
Analyses were performed using either Epi-Info or SPSS (SPSS
version 10.0, SPSS Inc., Chicago, IL) after exporting the data from
Epi-Info. Differences in proportions were assessed using Pearson’s
Chi
2 test, with p,0.05 considered significant. Multiple logistic
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patient factors and poor treatment outcomes. Two logistic
regression analyses were conducted: the first comparing treatment
success with death or treatment failure (defaulters removed); and
the second comparing treatment success with treatment default
(deaths and failures removed). All the factors considered in the
univariate analyses were entered into the multivariate analyses.
These factors were based on existing literature and suggestions
from the medical team involved in patient care.
RESULTS
Case finding
Between October 2003 and January 2005, 119 patients underwent
testing for drug resistance (Figure 1); 19 were patients previously
found to be infected with MDR-TB in the drug resistance survey
in 2001–2002, and 100 were suspected to have MDR-TB based on
previously failing a category-2 DOTS regimen. At that time, DST
was not routinely conducted in the DOTS program in the two
pilot districts, and only patients who could potentially be offered
treatment in the DOTS-Plus pilot underwent DST. The aim was
to have as few people as possible waiting for admission at any point
in time. Of the 119 patients, 108 (91%) were subsequently found to
have MDR-TB (including all the 19 cases from the drug resistance
survey). Therefore, among the 100 suspected MDR-TB cases, 89
(89%) were found to be infected with MDR-TB; the remaining 11
were all infected with strains with some level of drug resistance.
In total, 93 patients were started on treatment in the program;
this included 6 other drug-resistant cases (treatment outcomes not
shown). Of the 108 MDR-TB cases, 87 (81%) were started on
treatment. Of the remainder, the reasons for not starting treatment
included death before admission (11 patients, 10%), refusal to be
treated (8 patients, 7%), moved out of the district (1 patient, 1%)
and concomitant psychiatric disease precluding TB treatment (1
patient, 1%). While there were no significant differences in drug
resistance profile between MDR-TB patients starting treatment
and those not, those treated tended to have a greater level of pre-
existing second-line drug resistance. Treatment outcome results
are reported for the 87 patients in the cohort who started MDR-
TB treatment.
Baseline patient characteristics
Patients treated in this first cohort are described in Table 1.
Median age was 34 years, ranging from 17 to 72 years; 61% were
male. Patients had been ill with TB for a median of 4 years and
had received a median of four previous TB treatment episodes.
Overall, 44% of patients were classified as being in poor clinical
condition, and 70% had bilateral cavitary disease.
All patients had undergone a DOTS category-2 treatment
regimen at least once, and 90% of patients had failed a category-2
regimen at least once. Although all patients had been treated
within the DOTS program, 66% had also taken at least one
second-line drug indicating previous treatment outside of the
DOTS system. This drug was most commonly kanamycin, which
is widely available in Karakalpakstan.
The baseline resistance patterns are shown in Figure 2. High
levels of first-line resistance were observed, with 31 (36%) of 87
strains resistant to all five first-line drugs tested. Apart from
isoniazid and rifampicin, to which all strains were resistant, 85
(98%) of 87 were resistant to streptomycin, 52 (61%) of 85 were
resistant to ethambutol and 42 (49%) of 86 were resistant to
pyrazinamide.
Overall, 33 strains (38%) were resistant to at least one second-
line anti-TB drug. The most common second-line resistance was
to capreomycin (22/87, 25%) or kanamycin (21/85, 25%),
followed by ethionamide (15/86, 17%). No resistance to ofloxacin,
ethionamide or PAS was observed at baseline. Significant overlap
between capreomycin and kanamycin resistance was seen; all 21
strains with resistance to kanamycin were also resistant to
capreomycin, with one additional strain showing capreomycin
resistance, but not kanamycin. No patients were infected with
XDR-TB strains at the start of treatment, due to the absence of
resistance to ofloxacin.
MDR-TB treatment regimens
The majority of patients (52, 60%) were started on an
individualised regimen, based on known DST results. The
remaining 35 patients were treated with the empiric regimen,
with DST results available a median of 61 days (range 6–182 days)
after treatment initiation. For the majority of patients (25/35,
71%) started empirically, the receipt of DST results did not cause
any change to the regimen. For the 10 remaining patients, the
most common change to the regimen upon receiving DST results
was the removal of pyrazinamide, based on measured resistance.
Patients were started on a regimen containing a median of six
drugs (range 5–7) but were treated in total with a median of seven
drugs (range 5–10). This discrepancy reflects the 71 patients (82%)
requiring the composition of their treatment regimens to be
changed at least once during the treatment course (Table 2). The
most common drugs added to treatment regimens after treatment
initiation were ethambutol (not included in the ETR and where
susceptibility was later demonstrated on DST) and amoxicillin/
clavulanate (added as an additional agent when more efficacious
Table 1. Description of 87 MDR-TB patients started on
treatment
......................................................................
Patient characteristics
No. of patients
(%) N=87 Median (range)
Demographics
Male sex 53 (61)
Age 34 (17–72)
Rural residence 34 (39)
Previous imprisonment 15 (17)
Injection drug use (at admission) 2 (2)
Excessive alcohol use (at admission) 20 (23)
Tobacco use (at admission) 27 (31)
Receiving a pension 65 (75)
Health care worker 8 (9)
Previous TB treatment
Duration of TB disease (years) 4.1 (0.5–34)
Previous TB treatment episodes 4 (2–30)
Previous lung surgery 3 (3)
Previous use of at least one
second-line drug
57 (66)
Baseline clinical characteristics
Severe clinical condition* 38 (44)
Hemoptysis 30 (34)
Bilateral cavitary disease 61 (70)
Body mass index (BMI) 17.4 (11.7–28.0)
*Defined as one or more of the following: inability to walk unaided, high resting
respiratory rate (above 30/min) or BMI ,16.0.
doi:10.1371/journal.pone.0001126.t001
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reasons for stopping drugs in the regimen were the development of
resistance and severe adverse events (resulting in the permanent
removal of the drug from the regimen) (Table 3). Resistance, either
pre-existing or developed during treatment, was a significant cause
of stopping the first-line drugs included in the regimen, with
ethambutol and pyrazinamide stopped in about 40% of cases. In
contrast, the development of serious adverse events presumed to
be linked to particular drugs was most commonly responsible for
stopping second-line drugs, in particular ethionamide, cycloserine
and PAS. For a number of drug regimen changes, a reason was
not recorded in the system (Table 3).
Overall, 276 serious adverse events that resulted in a change to
one or more anti-TB drugs in the regimen were recorded among
Figure 2. Drug resistance among 87 MDR-TB patients started on treatment.
doi:10.1371/journal.pone.0001126.g002
Table 2. Numbers of patients treated with individual drugs, in
the starting regimen, added later, and stopped during
treatment
......................................................................
Started
in initial
regimen
Added
later
Total given
drug (% of
total patients)
Stopped during
treatment*
(% of total given)
First-line
H0 0 0 0
R 1 1 2 (2%) 0
E 11 19 30 (34%) 14 (47%)
Z 68 3 71 (82%) 34 (48%)
S 0 2 2 (2%) 2 (100%)
Second-line
Km 19 6 25 (29%) 2 (8%)
Cm 68 2 70 (80%) 8 (11%)
Ofx 86 1 87 (100%) 5 (6%)
Eto 79 2 81 (93%) 31 (38%)
Cs 83 4 87 (100%) 13 (15%)
PAS 84 2 86 (99%) 21 (24%)
Amx/Clv 14 38 52 (60%) 8 (15%)
Clz 3 11 14 (16%) 7 (50%)
*excluding drugs stopped as scheduled in the regimen, eg, the injectable agent
(capreomycin or kanamycin).
Abbreviations: H=isoniazid, R=rifampicin, E=ethambutol, Z=pyrazinamide,
S=streptomycin, Km=kanamycin, Cm=capreomycin, Ofx=ofloxacin,
Eto=ethionamide, Cs=cycloserine, PAS=p-aminosalicylic acid, Amx/
Clv=amoxicillin/clavulanate, Clz=clofazamine
doi:10.1371/journal.pone.0001126.t002
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Table 3. Reasons for permanently stopping individual drugs
during MDR-TB treatment
......................................................................
Drugs
given
No.
patients
given
drug
No. stopped
due to
resistance
(% of given)
No. stopped
due to adverse
events
(% of given)
No. stopped due
to other or
unknown reasons
(% of given)
E 30 11 (37%) 3 (10%) 0
Z 71 28 (40%) 4 (14%) 2
S 2 1 (50%) 1 (50%) 0
Km 25 0 2 (8%) 0
Cm 70 3 (4%) 3 (4%) 2
Ofx 87 5 (6%) 0 0
Eto 81 11 (14%) 19 (23%) 1
Cs 87 0 12 (14%) 1
PAS 86 0 20 (23%) 1
Amx/Clv 52 1 (2%) 2 (4%) 5
Clz 14 0 4 (29%) 3
Abbreviations: E=ethambutol, Z=pyrazinamide, S=streptomycin,
Km=kanamycin, Cm=capreomycin, Ofx=ofloxacin, Eto=ethionamide,
Cs=cycloserine, PAS=p-aminosalicylic acid, Amx/Clv=amoxicillin/clavulanate,
Clz=clofazamine
doi:10.1371/journal.pone.0001126.t003
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PLoS ONE | www.plosone.org 5 November 2007 | Issue 11 | e112667 patients (67/87, 77%). A wide range of adverse events were
attributed to the anti-TB drug regimen, including gastrointestinal
disturbances (32% of adverse events) and neuropathies (13%).
However, 54 (20%) did not have a clinical condition assigned.
Similarly, assigning particular drugs as responsible for adverse
events was often difficult; for 40 (14%) adverse events, multiple
drugs were recorded as potentially responsible. The drugs most
commonly held responsible were cylcoserine, ethionamide and
PAS. Among the 80 adverse events attributed solely to
cycloserine, 32 (40%) were described as neuropathies, 22 (28%)
psychoses and 10 (13%) acute depression. For ethionamide and
PAS, 30 (71%) of 42 and 28 (70%) of 40 adverse events,
respectively, were described as gastrointestinal. These adverse
events occurred throughout treatment, at a median of 7 months
into treatment for cycloserine (range 1–20 months), 8 months
(range 2–20) for ethionamide and 11 months (range 1–21) for
PAS.
Treatment outcomes
Treatment outcomes for the 87 patients started on treatment are
given in Table 4. Overall, 54 (62%) of 87 patients were recorded as
being successfully treated (cured and treatment completed) at the
end of treatment, 12 (14%) did not finish treatment, 13 (15%) died
during treatment and 8 (9%) were classified as treatment failures.
While little difference was observed in treatment success among
patients who were previously treated with second-line drugs,
compared with those only treated with first-line drugs, a significant
difference in the proportion defaulting treatment was seen: 33% of
those treated only with first-line drugs, compared with 4% of those
who reported taking a second-line drug for at least a month
(p=0.0001).
Among the 12 patients recorded as treatment defaults, the
median time to default was 6 months (range ,1–17 months). Of
the five patients who stopped treatment within the first 3 months,
none had converted to sputum culture negative at the time of
default. Among the remaining seven patients, six were culture
negative at the time of default; including one patient who was
culture negative for 13 months of treatment. One patient was still
culture positive at 6 months of treatment when they defaulted.
While extensive efforts were made to convince patients to restart
treatment (both immediately after patients stopped taking
treatment and after the 2-month period that defines default), only
one of the 12 patients was restarted on treatment, but
unfortunately defaulted from treatment again.
Of the 13 patients who died, only one died within the first
month of starting treatment. The remainder survived for a median
of 11 months of treatment (range 5–20 months). All but two of
these patients were classified as being in severe clinical condition at
treatment initiation, and two had undergone prior surgical
resection of the lung as part of previous TB treatment. TB was
considered by the treating physician to be an immediate or directly
contributing cause of death in 12 of the 13 deaths; the remaining
patient was a victim of homicide after 8 months of culture
negativity. Among the eight patients classified as treatment failure,
one was removed from treatment after 5 days due to a previously
unrecognised concomitant illness that precluded treatment, while
the remainder were removed from treatment due to failure of
therapy after a median of 15 months on treatment (range 10–
24 months). Of these, one patient died 4 months after stopping
treatment, while the remaining six were still alive as of November
2006. These six patients are further discussed below.
Treatment duration
Among successfully treated patients, the median total treatment
duration was 22 months (range 18–30 months), which was
a median of 18 months after culture conversion (range 16–
23 months). Only one patient was treated for less than 18 months
after culture conversion, as this patient became culture positive
again after 8 months of initial culture negativity. For this patient,
16 months of culture negativity with a total of 31 months of
treatment was considered sufficient. Lasting culture conversion
among successfully treated patients was achieved in a median of
3 months (range 1–15 months) and the injectable was given for
a median of 10 months after culture conversion (range ,1–
20 months), giving a total median duration for the injectable of
13 months among successfully treated patients (range 6–
24 months). For some patients, the injectable could not be
continued due to adverse events or drug resistance, and for
others, the injectable could not be stopped due to concern about
the total number of effective drugs remaining in the regimen. All
patients classified as failing treatment were continued on the
injectable for the duration of treatment.
Treatment interruptions
Treatment interruptions, in which all drugs were stopped for
a period of time, were due to adverse events, poor patient
compliance, or both. Overall, interruptions to treatment were
recorded for 84% of patients (73/87), resulting in a median of
18 days of treatment interruption per patient (range 0–117 days).
Among successfully treated patients, a median of five separate
interruptions occurred throughout treatment (range 0–17),
encompassing a median duration of 17 days (range 0–85 days).
This was not significantly different than the median of seven
interruptions among the treatment-failure patients, with a median
of 25 days of total treatment interruption.
Factors associated with poor outcomes
Factors that might be expected to have a potential impact on
treatment success, death or treatment failure, and treatment
default are shown by univariate analysis in Table 5. Since the
factors contributing to poor treatment outcomes are likely to be
different for the outcome of treatment default compared with the
outcomes of death or treatment failure, these outcomes have been
analysed separately. Resistance to second-line drugs and severe
clinical condition at treatment initiation were the only factors
significantly associated with the outcomes of death or failure in the
univariate analysis. Treatment interruptions, either $4 events or
Table 4. MDR-TB treatment outcomes by previous treatment
with second-line drugs
......................................................................
Outcome
Previously
treated with
first-line drug
only
Previously treated
with second-line
drugs Total
Cured 9 23 32
Completed 8 14 22
Treatment success 17 (57%) 37 (65%) 54 (62%)
Default 10 (33%) 2 (4%) 12 (14%)
Died 2 (7%) 11 (19%) 13 (15%)
Failure 1 (3%) 7 (12%) 8 (9%)
Total 30 57 87
doi:10.1371/journal.pone.0001126.t004
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PLoS ONE | www.plosone.org 6 November 2007 | Issue 11 | e1126$30 days total were not significantly associated with death or
failure on univariate analysis. In contrast, prior alcohol use (self-
reported), the presence of hemoptysis at admission and not having
taken second-line drugs previously were significantly linked to
default on univariate analysis.
In the multivariate analysis, severe clinical condition (OR 8.9,
1.6-50) and second-line resistance (OR 5.9, 1.6-22) remained the
only significant predictors of death or failure. Prior heavy use of
alcohol (OR 63, 2.8-1456) and severe clinical condition (OR 49,
1.7-1442) at the start of treatment were significant predictors of
default, with previous use of second-line drugs (OR 0.01, 0.001-
0.25) also remaining as a significant factor mitigating against
default in the multivariate model.
XDR-TB among treatment failures
The failure to effectively treat a significant number of patients
despite available second-line drugs is concerning. To assess the risk
posed to the community from the potential transmission of highly
drug-resistant strains harboured by these patients, the DST
profiles at the time of treatment failure for the six patients still
alive in November 2006 were assessed. Four cases of XDR-TB
were recorded at the time treatment was stopped among these 6
patients. A further case was also potentially XDR-TB, but the
cultured strain was measured to be rifampicin-sensitive at the time
of treatment failure (previously rifampicin-resistant). The remain-
ing treatment failure case, while developing resistance to the
second-line injectables kanamycin and capreomycin, did not show
resistance to ofloxacin. Thus, among six patients failing treatment
and remaining alive, five (83%; 6% of the total started on
treatment) were likely to be infected with XDR-TB strains.
Overall, five of these six patients were ambulatory and living in the
community in November 2006. The remaining patient was being
cared for in one of the TB sanatoria, ostensibly in isolation.
Reassuringly, no cases of XDR-TB were observed among patients
who later defaulted from treatment.
DISCUSSION
The provision of effective treatment for patients infected with drug-
resistant TB is essential, both on humanitarian grounds and if
further transmission of such strains is to be prevented. Results from
this first cohort of patients treated for MDR-TB in Karakalpakstan,
Uzbekistan are promising, with the proportion of successfully
treated patients comparable to that seen in other GLC-supported
DOTS-Plus projects [5]. Overall, 62% of patients started on
treatment were successfully treated. Living in a rural district did not
result in poorer treatment outcomes; if anything, rurality tended to
improve treatment outcomes, although this did not reach
significance. Themost commonfactors mitigatingagainst treatment
success (apart from treatment default itself) were, not surprisingly,
pre-existing resistance to any second-line anti-TB drugs and the
poor clinical condition of patients when started on treatment.
Since this was the first group of patients to be treated in
Karakalpakstan, and given the manner in which they were
recruited, these patients likely had longer durations of disease and
more previous unsuccessful treatment than later patients started on
treatment. Such conditions are likely to lead to higher levels of pre-
existing drug resistance and poorer clinical condition of patients,
which are factors found to be most related to death or treatment
failure in this analysis. With the expansion of the capacity of the
pilot project to treat more patients in 2004, and given the results of
this analysis, there has now been a change in the way MDR-TB is
diagnosed in the two districts currently covered by DOTS-Plus.
The policy now is for all patients diagnosed with sputum smear-
positive TB in these two districts to be routinely tested for drug
resistance and be transferred to DOTS-Plus, rather than wait for
these patients to fail DOTS treatment regimens. We therefore
might expect treatment outcomes to improve in subsequent
cohorts. However, the increasing availability of second-line drugs
on the open market and the unregulated use of these drugs may
lead to even higher levels of second-line resistance than that shown
here, with a consequent deleterious impact on treatment success.
Table 5. Univariate analysis of factors potentially contributing to the outcomes of death and failure (combined) and default.
..................................................................................................................................................
Factor
Treatment success
(n=54) %
Death or failure
(n=20) % p value
Default from
treatment (n=13) % p value
Baseline characteristics
Male sex 61 55 0.79 69 0.75
Age $40 years 24 40 0.25 46 0.17
Previous imprisonment 20 10 0.49 15 1.0
Excessive alcohol use (self-reported) 19 15 1.0 54 0.034*
$4 previous TB treatment episodes 57 70 0.42 62 1.0
Previous use of second-line drugs 69 90 0.076 15 0.001*
$4 years of TB disease 48 60 0.44 54 0.77
Rural residence 48 25 0.11 23 0.13
Resistance to second-line drugs (any) 28 70 0.01* 31 1.0
Severe clinical condition 54 90 0.006* 77 0.21
Bilateral cavitary disease 72 80 0.57 46 0.10
Hemoptysis 26 40 0.26 62 0.022*
Treatment characteristics
Started on empiric treatment regimen 35 40 0.79 62 0.12
$30 days of treatment interruption 21 40 0.14
$4 treatment interruptions 59 65 0.79 39 0.22
*p,0.05. P values compare treatment success to death or failure, and to default, respectively.
doi:10.1371/journal.pone.0001126.t005
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the proportion of patients defaulting treatment is also of concern.
Overall, 7% of patients found to be infected with MDR-TB strains
refused to be treated, and a further 14% of those started on
treatment defaulted. Since this was a new treatment program, with
a new hospital, anecdotal evidence suggests that initial scepticism
may have contributed to patients refusing treatment. Indeed, the
proportion of patients declining treatment has significantly reduced
over time, particularly when successfully treated patients started to
be seen in the community (unpublished observations).
Factors contributing to default from treatment included high
alcohol use (assessed at treatment initiation) and the presence of
hemoptysis at admission, whereas previous use of second-line
drugs was a mitigating factor. Since the use of alcohol was strongly
discouraged during treatment, particularly during hospitalisation,
and given the high level of alcohol consumption in general in
Karakalpakstan, it is not surprising that prior heavy alcohol use
was predictive of default. Among subsequent cohorts of patients,
much emphasis has been placed on psychosocial care and support
for patients, particularly those suffering from alcohol addiction,
with the aim of creating a patient-centred approach to care.
The rationale behindthe findingthat hemoptysis is alsorelated to
default is not clear. It is possible that patients consider coughing up
blood to be a sign of impending death and consequently feel that
treatment will not be successful once this point is reached.
Alternatively, patients whose hemoptysis resolves with treatment
might consider themselves ‘‘cured’’ and hence stop treatment.
Patients who report previous use of second-line drugs appear to be
morelikelytostayontreatment,whilealsomorelikelytobe infected
with strains with second-line resistance. Previous use of second-line
drugs may be a marker for patients who are more committed and
motivated to receive and stay on treatment, as these patients have
sought out private treatment and paid for these drugs. Or it may be
that patients who could afford to purchase second-line drugs in the
past have better socioeconomic circumstances and support
structures that might mitigate against default. Further qualitative
research into the reasons behind default should aid appropriate
programmatic responses to reduce the default rate.
The use of an ETR while waiting for DST results did not
appear to impact treatment outcomes, based on the absence of
significant associations in the univariate and multivariate analyses
and on the limited regimen changes occurring when DST results
became available. This suggests that empiric regimens (designed
according to the prevailing resistance profiles) are an appropriate
mechanism for starting suspected MDR-TB patients on treatment
earlier. Although a large proportion of patients started on
pyrazinamide as part of the ETR were later taken off this drug,
its inclusion in the ETR is justified based on its effectiveness
among those who might be susceptible. Similarly, the inclusion of
ethambutol in the ETR might be justified, given the proportion of
patients with strains susceptible to this drug and its relative
tolerability and activity against Mycobacterium tuberculosis.
The high proportion of patients requiring changes to their
treatment regimen, based on both drug resistance and adverse
events, suggests that close monitoring and frequent assessment of
sputum culture and drug resistance where patients remain or
become sputum culture-positive during treatment is essential. The
high levels of regimen change and adverse events experienced
during treatment reflects the complexity of treatment and the
inputs, both medical and laboratory-related, that were required to
treat this first cohort of patients. Although the current analysis
shows that such treatment is feasible, the level of inputs required
reflects the difficulties involved in scaling up drug-resistant TB
treatment in settings such as Karakalpakstan.
Scaling up DOTS-Plus should also be tempered by the risk of
creating XDR-TB cases. Five patients (6% of the total started on
treatment) remained alive, with a high likelihood of continuing to
harbour these essentially untreatable TB strains. In this setting, as
indeed elsewhere, no further treatment options exist for these
patients. Therefore, treatment failure in Karakalpakstan, although
at a comparable level to other DOTS-Plus projects, comes at a high
cost. To date, no data have been published on the numbers of
XDR-TB patients coming out of DOTS-Plus projects. To assess the
exact mechanisms and contributors to XDR-TB development,
further analyses involving detailed assessment of regimens,
compliance and treatment interruptions, along with DNA finger-
printing and testing for mutations contributing to resistance are
required. The development of XDR-TB from a project implemen-
tedundercurrent best-practiceguidelineshighlightsthe urgentneed
for more effective drugs to treat MDR-TB. In the meantime,
strategies to determine the circumstances under which patients with
pre-existing XDR-TB should be offered second-line treatment are
needed, as is a further discussion of second-line regimens that
include all available drugs to which the organism is susceptible to
reduce the risk of XDR-TB. In addition, programs need to be
responsible for supporting patients who fail treatment with XDR-
TB, to reduce the risk of further community transmission.
Since this was a programmatic evaluation, a number of
limitations should be considered. The relatively small sample size
restricts the scope of analyses that canbe conducted. Forexample, it
is not possible to compare treatment outcomes among patients
receiving different treatment regimens due to the range of resistance
profiles and variety of regimens (with changes throughout
treatment) used. Other limitations include the case-finding strategy
employed for this first group of patients, resulting in perhaps the
most difficult group of patients to treat, along with logistical
constraints resulting in delays in treatment initiation, whereby there
is more opportunity for strains to become more drug resistant. In
addition, the relatively high default rate renders the assessment of
treatment efficacy difficult if patients manage to stay on treatment.
In conclusion, these first results from a pilot MDR-TB treatment
program in Karakalpakstan, Uzbekistan are acceptable, given the
severity of disease and level of drug resistance in the first cohort.
These results suggest that treatment in high-prevalence MDR-TB
settings is feasible, even in rural areas, albeit resource intensive and
difficult for patients and staff. Further simplification and standardi-
sation of regimens would make scaling up treatment more
practicable, but potentially increases the risk of XDR-TB de-
velopment.
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